Deciphering a short text in mid-10th century Greek bookhand - β???????

Post date: 2021-03-05 03:36:33
Views: 198
On the basis of two online images of a meticulously lettered paragraph in two early copies of Dioscorides' De Materia Medica - one smaller, colour one from the Morgan manuscript, and one larger, more distinct, black&white one from the Vienna manuscript - would anyone be able to help transcribe and possibly translate the text? (My previous appeal for a classical Japanese page found great help from the hive mind!)

The text pertains to the first illustration on the page, of a stag's head - the inscription next to it (in the Morgan, above it in the Vienna) reads: "elaphou kephale" - and I am lead to believe (by a third, knowledgable source) the text actually deals with a kind of aphrodisiac tuber/fungus. It's part of a section absent from most other copies of Dioscorides seminal work, so I haven't been able to locate a version either transcribed or translated. And, full disclosure, I have no level of Greek, least of all its medieval majuscule bookhand version, so I'm kind of stuck... TIA for any pointers or assistance!
Number of Comments
Please click Here to read the full story.
 
Other Top and Latest Questions:
Trump administration equity stakes pose risks to U.S. companies and markets
The Trump administration equity portfolio is growing. These are the investments so far
Couple bought a 140-year-old New Jersey home for $550,000 and spent $172,000 renovating it—take a look inside
Here are the 5 big things we're watching in the stock market this week
Trump’s 'big beautiful bill' may spur significant changes to higher education in 2026 and the rise of 'un-college,' experts say
Hims & Hers pulls copycat weight-loss pill after threats of legal action
Washington Post publisher Will Lewis announces departure, following mass layoffs
Tech giants in China sold off alongside their U.S. peers last week. How to play it
U.S. plans initial payment towards billions owed to the UN, envoy Waltz says
Goldman Sachs says this under-the-radar biotech play could more than double in value